hero image
Sharad Ghamande - Augusta University. Augusta, GA, US

Sharad Ghamande Sharad Ghamande

Director of Gynecology Oncology | Georgia Cancer Center at Augusta University


Dr. Sharad Ghamande leads the team of gynecologic oncologists and oversees the clinical trials program at the Georgia Cancer Center.





loading image loading image loading image loading image




Dr. Sharad Ghamande is the executive vice chair of the MCG Department of Obstetrics and Gynecology and the chief of Gynecologic Oncology at the Medical College of Georgia in Augusta, Georgia. Along with his work with gynecological oncology patients, Dr. Ghamande is heavily involved in each and every clinical trial happening at the Georgia Cancer Center. He believes that clinical research offers patients tomorrow's treatments available today. As an oncologist, he believes clinical trials can play a vital role in improving a patient's quality of life. While not every cancer can be "cured," Dr. Ghamande believes it finding options to turn a person's cancer into a chronic disease allowing them to live a more normal life.

Areas of Expertise (8)

Gynecologic Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Uterine Cancer

Vaginal Cancer

Vulvar Cancer

Cancer clinical trials

Accomplishments (3)

America's Top Doctors/ Top Doctors for Cancer (professional)

Dr. Ghamande was named one of the nation's top doctors published by Castle Connolly Medical Ltd., the America’s Top Doctors online database and companion book designates physicians who are regarded by their peers and other health care leaders as among the very best in their field for specific diseases and medical techniques. Doctors do not and cannot pay to be included in any Castle Connolly guide or online directory.

Distinguished Doctor (professional)

Presented by the Expert Network

Distinguished Faculty Award (professional)

Presented by the Medical College of Georgia's Faculty Senate

Education (1)

University of Bombay: Doctor of Medicine

Media Appearances (3)

The Georgia Cancer Research Center develops a new option than chemotherapy to treat ALL cancers

News Channel 6  tv


The Georgia Cancer Center is just one cancer center in the country developing immunotherapy options for cancer patients. Dr. Esteban Celis and Dr. Sharad Ghamande are treating select patients with this new alternative to traditional chemotherapy.

view more

JENNIE: January is Cervical Cancer Awareness Month

News Channel 6  tv


Dr. Sharad Ghamande is working tirelessly to lower the death rate from the disease. He is the Obstetrics and Gynecology Department Chair at the Medical College of Georgia at Augusta University.

view more

SPECIAL REPORT: Overcoming Racial Disparities in Cancer Trials

News Channel 6  tv


The Georgia Cancer Center is also one of 12 designated sites in the US to have the Minority N-CORP Designation. These sites involve community hospitals, oncology practices, and integrated health care systems... where patient populations are at least 30% racial/ethnic minorities or rural residents.

view more

Articles (1)

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

Journal of Clinical Oncology

Naumann, R. W., Coleman, R. L., Burger, R. A., Sausville, E. A., Kutarska, E., Ghamande, S. A., ... & Gersh, R. H.

2013 Vintafolide (EC145) is a folic acid–desacetylvinblastine conjugate that binds to the folate receptor (FR), which is expressed on the majority of epithelial ovarian cancers. This randomized phase II trial evaluated vintafolide combined with pegylated liposomal doxorubicin (PLD) compared with PLD alone. The utility of an FR-targeted imaging agent, 99mTc-etarfolatide (EC20), in selecting patients likely to benefit from vintafolide was also examined. Women with recurrent platinum-resistant ovarian cancer who had undergone ≤ two prior cytotoxic regimens were randomly assigned at a 2:1 ratio to PLD (50 mg/m2 intravenously [IV] once every 28 days) with or without vintafolide (2.5 mg IV three times per week during weeks 1 and 3)...

view more